Hindware Home Innovation Limited is launching a Rights Issue worth Rs 249.70 crore, available for subscription from 7 November 2024 to 22 November 2024. Shareholders will be entitled to 119 Rights equity shares for every 758 fully paid-up equity shares they own as of the record date, 25 October 2024. Each share has a face value of Rs. 2, and the issue price is set at Rs. 220 per share.
Stay tuned with us for comprehensive details on the Hindware Home Innovation Ltd 2024 Rights Issue, including the issue size, entitlement, payment terms, and more.
Corporate Action | Details |
---|---|
Security Name | Hindware Home Innovation Limited |
Issue Open/Close | November 7, 2024 - November 22, 2024 |
Record Date | October 25, 2024 |
Issue Size (Amount) | ₹249.70 Crores |
Issue Size (Shares) | 11,349,962 |
Right Issue Price | ₹220 per share |
Face Value | ₹2 per share |
CMP | ₹301 |
Renunciation of Rights Entitlements | November 18, 2024 |
Terms of Payment | The full amount of the Issue Price will be payable on application |
Entitlement | 119 Rights Equity Shares for every 758 fully paid-up Equity Shares held on Record Date |
Disclaimer: The Information compiled by CEBPL on a best efforts basis from information CEBPL received from third party vendors, believed to be reliable. The information may contain errors or omissions; and is subject to change without prior or additional notice. CEBPL provides corporate action information that may be of interest or relevance to CEBPL clients. This does not constitute a recommendation or advice by CEBPL, and CEBPL Clients may not rely upon it. CEBPL does not warrant that the information provided is accurate, timely, or complete. CEBPL Clients are urged to verify the information prior to using it in their investing and trading decisions, including, but not limited to, referral to independent financial news resources, company announcements, and regulatory filings or disclosures. "Investment in securities market are subject to market risks, read all the related documents carefully before investing". Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of retums to investors. Name of Compliance Officer-Prashant Salian Email Id-Prashant.salian@choiceindia.com Contact no. 022-67079999-Ext-2310. Name of Grievance Officer-Deepika Singhvi-Email Id-ig@choiceindia.com, Contact no. 022-67079999-Ext-834. choiceindia.com
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.